TuHURA Biosciences and Kineta Announce Significant Merger Approval and Future Directions TuHURA Biosciences and Kineta announce the stockholder approval of their merger, paving the way for growth in innovative immunotherapy solutions.

TuHURA Biosciences and Kineta Announce Significant Merger Approval and Future Directions #USA #Tampa #TuHURA_Biosciences #KVA12123 #Kineta_Inc.

Breaking New Ground in Melanoma Treatment: TuHURA and Kineta's Latest Findings Discover the latest results from TuHURA Biosciences and Kineta regarding advanced melanoma treatment from their Phase I-II study presented at AACR.

Breaking New Ground in Melanoma Treatment: TuHURA and Kineta's Latest Findings #United_States #Chicago #TuHURA #Kineta #KVA12123

TuHURA Biosciences to Present at 2025 AACR Annual Meeting on Innovations in Cancer Immunotherapy TuHURA Biosciences is set to present groundbreaking research at the AACR Annual Meeting in Chicago, focusing on advanced cancer treatments and technologies.

TuHURA Biosciences to Present at 2025 AACR Annual Meeting on Innovations in Cancer Immunotherapy #USA #Chicago #TuHURA_Biosciences #KVA12123 #IFx-Hu2.0